Klemens Budde

MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

FTY720 (fingolimod) in renal transplantation.

S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.

Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients.

Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring.

Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.

Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature.

Pharmacokinetic principles of immunosuppressive drugs.

Outcomes of transplanting deceased-donor kidneys between elderly donors and recipients.

Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.

The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.

Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.

Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.

Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.

Target enzyme activity as a biomarker for immunosuppression.

Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.

Enteric-coated mycophenolate sodium.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients.

Biomarkers of over-immunosuppression.

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation.

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Tacrolimus only for breakfast ….

About incidence and timing of donor-specific antibodies after graft nephrectomy.

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

Non-invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography.

Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications.

Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors.

Human leukocyte antigen-incompatible kidney transplantation after "desensitization"--hope and reality.

Building a network of ADPKD reference centres across Europe: the EuroCYST initiative.

Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.

Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.

Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients.

The need for minimization strategies: current problems of immunosuppression.

Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.

'Suspended in a paradox'-patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies.

Midterm echocardiographic follow-up of cardiac function after living kidney donation.

[Cytomegalovirus after renal transplantation - diagnosis, prevention and treatment].

Advances in pharmacotherapy to treat kidney transplant rejection.

Current status of immunosuppressive minimization and tolerance strategies.

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.

[Immunosuppression and its use in kidney transplantation].

Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.

Therapeutic Drug Monitoring of Everolimus: A Consensus Report.

Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy.

Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.

'I feel stronger and younger all the time'-perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research.

Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?

Improved Left Ventricular Structure and Function After Successful Kidney Transplantation.

Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection.

Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection.

Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide.

Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.

Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation.

A novel tool for the identification of correlations in medical data by faceted search.

Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.

Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.

Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops.

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals.

Adjustment of target weight based on absolute blood volume reduces the frequency of intradialytic morbid events.

The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review.

Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.

Transplanting HCV-Infected Kidneys into Uninfected Recipients.

Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.

Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.

Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board.

Any Progress in the Treatment of Antibody-Mediated Rejection?

Assessment of the Kidney Donor Profile Index in a European cohort.

Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients.

Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.

Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results.

Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.

Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications.

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial.

Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.

[Digital Nephrology].

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.

Diagnostic Utility of Exome Sequencing for Kidney Disease.

Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.

Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes.

Risks and benefits of everolimus.

Predictors of graft survival at diagnosis of antibody-mediated renal allograft rejection: a retrospective single-center cohort study.

Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome.

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.

Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives.

Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: A retrospective study.

Is a Retroaortic Vein a Risk Factor in Laparoscopic Living Donor Nephrectomy?

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.

Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases.

Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.

Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay.

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.

Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles.

Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients.

Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMI.

eHealth in transplantation.

Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center.

Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation.

The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single-center cohort study.

The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study.

Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.

A 2020 Banff Antibody-mediatedInjury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study.

A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.

Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients.

What happens after graft loss? A large, long-term, single-center observation.

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection.

STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany.

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation.

Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19.